CLC bio delivers specialised immunoinformatics solution to Symphogen
1 September 2009
CLC bio has completed a specialized immunoinformatics system that is
fully customized to fit into Symphogen’s proprietary Symplex technology
for high throughput identification of antibodies with diversity and
specificity customized to a particular therapeutic application.
CLC bio has developed a CLC Main Workbench plug-in, which is designed
to optimize the end-to-end workflow and analysis pipeline when working
with the large number of antibodies retrieved during the Symplex
process.
“When investigating the diversity and complexity of disease-relevant
antibody repertories from human donors, speed and quality are essential.
Thus, the faster we can go through our initial bioinformatics workflow
and identify a diverse panel of complementary antibodies of interest,
the earlier we can compose the optimal recombinant polyclonal antibody (rpAb)
drug lead candidate to advance into development - this is of course of
the utmost importance to us” says Director of Antibody Discovery at
Symphogen, Dr. Allan Jensen, PhD.
“CLC bio has fully integrated the workflow by automating all the
steps in the downstream bioinformatics analysis process. Not only has
this accelerated the research process tremendously by eliminating
tedious and complicated manual procedures but it also removes the
overhead of keeping third party software running and updated - and in
turn it provides a high quality and robust workflow.”
Director of Consulting Services at CLC bio, Dr Jannick D Bendtsen,
said, “Where Symplex is a cutting-edge concept for testing on humans and
in the lab, Symphogen’s new special plug-in is designed to analyze the
sequencing data coming from all these research projects, and integrate
them nicely into an end-to-end workflow. We are proud to deliver this
intricate solution to Symphogen, which stresses the flexibility and
stability that our overall bioinformatics platform provides, and we look
forward to seeing Symphogen’s projects coming faster through their
development phases.”
Bookmark this page